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R esults   
Cancer incidence is increasing 
worldwide. In Europe 30, in 2006, over 
2.4 million new cancer cases were diag-
nosed, which means a 10% increase 
compared to 2002 incidence.  
In the same time, all-cancers mor-
tality rate is slowly starting to recede, 
with only a 0.37% increase between 
2002 to 2006 (GLOBOCAN 2002, Fer-
lay 2006).  
This is due to progress in screening 
and better available treatments, both 
reflected in a positive trend in cancer 
survival.   
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Abstract 
 
Objective: Aim of the study is to show the burden and cost of cancer, to overview 
the resources available for cancer treatment in European countries including 
Romania, and see how these relate to the countries market access for new oncology 
drugs. 
 
Methodology An analysis of burden of cancer in European countries was 
performed by looking at various disease indicators from international studies, with a 
comparison per types of cancer for Romania based on local market research and a 
retrospective descriptive study on data from National Hospital database for 2008. 
 
Results: The incidence of cancer in European countries is increasing, top three 
cancers as number of cases are breast, colorectal and prostate cancer. There are wide 
variations between European countries regarding resources allocated to cancer therapy and 
absorption of new oncology drugs. Romania is among countries with the lowest spending 
for cancer treatment in EU although cancer incidence is comparable with other Eastern 
European countries. The most frequent types of cases hospitalized are for breast, colorectal 
and lung cancer. Cases are treated in day hospital and inpatient settings, and they are 
usually associated with intravenous chemotherapy and surgical procedures, resulting in a 
large number of episodes of care. 
 
Conclusions: In Romania, case-mix data can be used to show the real burden of 
cancer, in terms of evolution of volume of cases per types of cancer and per diagnoses. 
Costs of care for cancer patients are high, but most part (2/3) represent indirect costs, such 
as costs with loss of productivity due to disease, which generate an important economic 
burden for the society. In this holistic perspective, high costs of new therapies are in most of 
cases outweighed by future benefits from prolonging life and increased quality of life for 
cancer patients. Based on the analysis, important issues to be addressed in near future are 
the inequity in access between different regions to specialized oncologic care, and the delays 
in market uptake of new oncology drugs due to delayed reimbursement decisions following 
market authorization. Also, a functional National Cancer Registry (still under development) 
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I ntroduction   
The main purpose of this article 
is to show the burden and cost of can-
cer, to overview the resources avail-
able for cancer treatment in European 
countries including Romania, and see 
how these relate to the countries mar-
ket access for new oncology drugs. 
 
M etodology  An analysis on the burden 
of cancer in European countries was 
performed  using data used from 
Karolinska Institute Comparator Re-
port on Patient Access to Cancer 
Drugs in Europe (2009) and two in-
ternational studies (GLOBOCAN 
2002, Ferlay 2006). 
Additionally, an analysis of can-
cer indicators and a comparison per 
types of cancer for Romania based on 
local market research (CEGEDIM, 
2009) was made. In the same time, a 
retrospective descriptive study was 
performed, using data from National 
Hospi tal  database for  2008 
(NSPHHSM).  
     Data regarding hospital utilization 
for cancer is from NCOIISB (data 
available for 2007).  
Absolute numbers and percent-
ages were used to compare distribu-
tions stratified per age group, sex, 
type of residence, type of admission, 
average length of stay, the surgical 
procedures performed on these cases, 
and for comparison of different types 
of cancer. 
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1. The burden of cancer in Euro-
pean countries  
Research of available studies 
showed that the highest volume of 
cases in EU 25, Switzerland, Iceland 
and Norway is registered for breast 
cancer, followed by prostate and 
colorectal cancer, with over 300,000 
cases each. The first two cancer 
types are not only frequent, but also 
show the highest increase of inci-
dence rate between 2002 and 2006: 
18.51% for breast cancer and 
54.25% increase for prostate cancer. 
An increasing incidence rate (by 
21.46%) for the same period was 
noted for lung cancer in female, 
which also presents an increase of 
the mortality rate (by 21.11%). 
Causes for evolution of incidence 
and mortality for types of cancer are 
documented in literature (such as 
extensive screening for prostate can-
cer, or increased tobacco consump-
tion among women for lung cancer); 
however, there are significant differ-
ences in incidence and mortality 
developments between cancer types, 
and this is the first divergence noted 
in the Comparator Report on Patient 
Access to Cancer Drugs in Europe, 
from Karolinska Institute (Wilking 
et al., 2009).  
 
The Comparator Report on Pa-
tient Access to Cancer Drugs in 
Europe (from now on  Karolinska 
Report 2009) also shows the geo-
graphical divergence across Europe. 
Hungary’s incidence rate is almost 
double of that of Bulgaria or Roma-
nia, and the difference between male 
and female incidence is much 
smaller in the Nordic countries such 
as Denmark, Iceland or Sweden, 
than among eastern and Southern 
Europe (Belgium, France, Italy, 
Greece or Spain). With regard to 
mortality rates due to cancers in 
2006, the Report shows higher than 
Europe average rates for the Central 
and Eastern Europe countries. 
 
The most common measurement 
of the cancer burden used by WHO 
is Disability adjusted life years 
(DALYs), which combines both 
mortality and disability. In 2002, 
WHO estimated that more than 10 
million DALYs were lost in the 
European countries due to cancer 
(third most prominent in terms of 
burden, after mental illnesses and 
cardiovascular diseases), which ac-
counts, on average for about 16% of 
all DALYs lost in each country. For 
the same year, WHO estimated that 
in Romania about 12% of all DALYs 
were lost due to cancer. 
 
Besides the burden of cancer on 
those suffering from cancer and their 
relatives, there is also an economic 
burden associated with the disease, 
in terms of costs of treatment and 
losses in productivity. Overall, in 
Europe the expenditure per capita for 
cancer in 2005 was 148€ (Eurostat, 
2007) compared to 124€ in 2004, 
representing 6.3% of total healthcare 
expenditure. The health care expen-
diture for cancer for European coun-
tries is between 4-7% of the GDP, 
significantly lower than the share of 
the burden of cancer, which, as pre-
viously showed, accounts for 16.7 
percent of all ‘healthy’ years lost in 
the European Union. From the eco-
nomic burden of cancer, indirect 
costs (with losses of productivity, 
informal care from relatives and 
other non-medical services) account 
for two-thirds. Direct health care 
costs and drugs account for approxi-
mately 7% and 13% respectively, of 
all health care costs for cancer.  
 
Country comparisons are diffi-
cult, due to different percentages of 
GDP allocated overall to healthcare, 
as well as to the different share allo-
cated to cancer treatment. However, 
lower expenditures (direct costs of 
cancer) can be observed in the coun-
tries with lower percentage of GDP 
allocated to healthcare (Karolinska 
Report, 2009). France, Germany, 
Luxembourg, Austria, Norway, Swe-
den and Switzerland spend more than 
200€ per capita for cancer treatment, 
followed by Iceland, Ireland, Den-
mark, Belgium with 180-195€, and 
with some lower values, but still over 
100€, Netherlands, Spain, Italy, United 
Kingdom, Portugal and Greece. At the 
lower base, a cluster of countries spend 
less than 50€ per capita for treatment 
cancer, such as Poland, Slovakia, Esto-
nia, Latvia, Lithuania and Bulgaria. 
Romania, with 22€ per capita in 2005, 
represents the country with the lowest 
spending for cancer treatment in EU, 
although cancer incidence compares 
with other Eastern European countries.  
 
Hospitalization is the largest single 
item of the direct costs in cancer care in 
European countries, although the num-
ber of patients hospitalized is increas-
ing, and the number of bed days is de-
creasing (Karolinska Report, 2009). The 
decrease in number of bed days does 
not necessarily represent savings, since 
it is a common trend in most countries 
to shift care to outpatient settings. Also, 
there is an increase in availability of 
new treatments.  
 
Cost of drugs represents an increas-
ing share in the total direct cost of can-
cer, due to new indications for already 
approved drugs, as well as introduction 
of new ones. In the same time, im-
proved treatment may lead to improve-
ments in survival and therefore longer 
periods of treatment.  
In 2004 the estimated cost of drugs 
reached approximately 13% of total 
cancer costs in the EU (Jonsson and 
Wilking, 2007), and this is rising.  
 
Total sales of oncology drugs in 
Europe have increased substantially 
over the period 1998-2007 from €4.3 
per capita to €26.3 per capita, mainly 
due to introduction of new innovative 
drugs. Sales in 2007 in different coun-
tries reveal highest values (over 3 mil-
lion € /100,000 inhabitants) for France, 
Switzerland, Austria, Denmark and 
Czech Republic, and lowest (under 
500,000€ /100,000 inhabitants) for Lat-
via, Lithuania, Bulgaria and Romania.  
 
Most of cancer drugs sold (68%) 
were introduced on the market before 
1999, 17% were introduced between 
1999-2002, 11% between 2003-2005, 
and only 3% were introduced in 2006-
2007.  
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Comparison of proportion of 
new cancer drugs (introduced in 
2006-2007) from total cancer drug 
sales in EU 28 countries in 2007 
indicate the lowest uptake for Roma-
nia and Bulgaria; almost 80% of 
sales were for drugs introduced be-
fore 1998, and about 5% for those 
introduced in 2003-2005.  
 
Main barriers in uptake of new 
oncology drugs are in most countries 
financially driven, due to the budg-
ets constraints; however, delays be-
tween market authorization of new 
drugs and reimbursement decisions 
are often very long, as most coun-
tries treat these two processes sepa-
rately. Examples are France, Hun-
gary, Italy, Slovakia, Belgium, Aus-
tria, Greece and Spain with almost 1 
year or more delay between approval 
and market access (much longer than 
the 180 days stipulated by EU regu-
lation),  whereas in Central-East 
European countries delays are more 
than 200 days (Poland - 214 days, 
Czech Republic - 270 days and Slo-
venia - 281 days).  
In some countries, as shown in 
Karolinska Report 2009, delays are 
dependent on the way of administra-
tion, as, for example, cancer drugs in 
hospital use become readily avail-
able in hospitals once approved. Ex-
ceptions are Germany and United 
Kingdom where approval of drugs 
and reimbursement occur simultane-
ously; however, some barriers in 
access arise from limited budgets for 
drugs at prescribers level (Ger-
many), or strict evaluations from 
technology assessment bodies (such 




2. Case study - the burden of can-
cer in Romania  
 
A study for the research of local 
oncology market was conducted by 
Cegedim in April-May 2009, and 
involved 60 oncologists from Bu-
charest, some large towns (>250,000 
inhabitants, assimilated with univer-
sity centers) and medium towns 
(50,000 - 250,000 inhabitants, as-
similated with capitals for districts), 
the sample being statistically repre-
sentative for national level.  
The results of the study show 
that an oncologist has on average for 
follow-up 2,140 patients with any 
type of cancer. Every month he has 
about 230 cancer patients for treat-
ment, most of them having breast 
cancer, followed by those with colo-
rectal and lung cancer.  
 
While for breast cancer and colo-
rectal cancer the ratio between pre-
metastasis stages and metastasis 
stages for new patients is 2/1 and 
4/3, for lung cancer most of the pa-
tients (3/2) are diagnosed when they 
already are in a metastatic stage.  
Additionally, for breast and colo-
rectal cancer only about 15% of pa-
tient in pre-metastasis stage develop 
metastasis during the first year after 
the diagnosis.  
Not the same profile of evolution 
for the lung cancer, where 45% of 
the new patients in pre-metastasis 
stage develop metastases. 
 
 
3. Analysis of cancer pathology 
hospitalized in 2008 in Romania  
 
The analysis was performed for 
118 diagnoses of cancer reported as 
principal diagnosis for day-hospital 
patients and inpatients discharged 
from Romanian hospitals (covering 
both acute and chronic care).  
The study refers to patients with 
breast cancer, colorectal cancer, lung 
cancer, non Hodgkin lymphoma, 
lymphatic chronic leukemia, pan-
creas cancer, brain cancer, gastric 
cancer, renal cancer, prostate cancer, 
cervix and ovarian cancer.  
These categories account for 
202,949 cases, which represents 4% 
of all discharges at national level in 
2008. Out of total number of cases, 
88% were treated as inpatients (57% 
acute, 43% chronic cases), and 12% 
were treated as day-hospital, in hos-
pital ambulatory settings.  
 
From all cases of cancer reported 
by hospitals in 2008, one quarter are 
over 70 years old and 53.6% are men. 
Most of the patients (over 60%) are 
from urban areas, 70% of cases are 
treated in hospitals located in their dis-
trict of residence, while 30% of them 
have to travel in another district for re-
ceiving care. The majority of patients 
(98.3%) are treated in acute care facili-
ties.  
 
The average length of stay (ALOS) 
is about 7 days for acute care patients, 
and 11 days for chronic care patients. 
Regarding the type of admission 
(Figure 1), about half of the cases are 
admitted with referral from the special-
ist physician.  
 
 
The costs of hospital treatment for 
cancer cases are high, since 87.6% of 
cases have also a secondary diagnosis 
(complications and/or co-morbidities), 
and for 95% of patients at least one 
medical procedure was reported.  Un-
fortunately, the lack of cost data on hos-
pital services for these patients sets 
some limits for the analysis of burden 
of cancer related to hospital services. 
 
Distribution of number of cases per 
type of cancer (Figure 2) shows that on 
first places are colorectal, lung and 
breast cancer, each of them accounting 
for almost 20% of all inpatient cancer 
pathology. 
Almost 40% of inpatient cases with 
cancer have one of the following diag-
noses: 
• Malignant breast tumor, unspecified - 
14,329 cases, representing 8.4% from 
all cancer cases; 
• Malignant rectal tumor - 11,224 
cases, which represent 6.6% of all 
cancer cases; 
• Malignant ovarian tumor - 10,944 
casesMalignant tumor of bronchial 
and lung, unspecified - 10,202 cases, 
which represent 6% of all cancer 
cases; 
• Malignant tumor in upper-external 
quadrant of the breast - 9,711 cases, 
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• Malignant tumor upper lobe, 
bronchial and lung - 9,545 cases; 
• Malignant tumor of prostate - 
8,729 cases, representing 5.1% of 
all cancer cases;  
• Malignant tumor of cervix - 5,781 
cases. 
In day-hospital care 23,614 
cases were treated, totalizing 40,976 
episodes, with a mean of more than 





From the total of 42,263 cases, some 
9,070 cases were treated in day hos-
pital settings, accounting for 17,442 
services, with an average of 15.2 
visits or services per case treated.  
From all inpatients with breast can-
cer, the 70 years old and over repre-
sent 15.7% of the cases, which is 
lower comparing to the percentage 
when considering all cancer types 
(25%).  
The ALOS is 6.6 days, slightly 
lower than the mean for all cancer 
cases (7 days).  
A difference in type of admission to 
hospital could be noticed, almost 
70% from breast cancer patients are 
admitted with referral from special-
ist, while for all types of cancer 49% 
of patients have a specialist referral. 
  
Only to 16% of breast cancer patients 
were performed some surgical proce-
dures, and the most frequent was simple 
mastectomy, unilateral and excision of 
breast injuries. Intravenous chemother-
apy (1-6 hours) was reported as secon-
dary procedure for 12,645 cases (about 
30% of total number of cases with 
breast cancer).  
 
Colorectal cancer (CRC) 
 
A total of 37,641 cases were treated for 
CRC, out of which 4,257 cases treated 
in day-hospital settings, accounting for 
7,858 services, with a mean of 11.3 ses-
sions/case. 
A higher percentage (28.6%) are pa-
tients over 70 years old, than the mean 
for all cancers (25%); 56.4% from cases 
are men. Most of cases (55.3%) are ad-
mitted with a referral from the specialist 
(comparing to 49% for all cancer 
types). 
Figure 1 – Distribution of cancer cases by type of admission to hospital in 2008 
Figure 2 – Distribution of number of cancer cases by localization of disease for all discharges in 2008  
Data source: NSPHHSM, 2008 
Data source: NSPHHSM, 2008 
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Another important aspect is the high 
percentage of cases admitted as emer-
gencies, 38.5% versus a 21% for all 
cancers. From all inpatients, 21.4% un-
derwent surgical procedures, the most 
frequent being the ablation of cerebral 
tumor and ablation of cerebellums tu-
mor. CT scan was performed for 1,940 
of cases with brain cancer. 
 
Renal cancer  
 
A total of 4,215 cases (2.3% of all can-
cer cases) were treated as inpatient and 
day-hospital care.  
A smaller percentage (19.5%) are over 
70 years old than for other types of can-
cer, so patients tend to be younger.  
ALOS was 8 days, and 34.5% of cases 
were admitted with referral from the 
family doctor versus the average of 
27% for all types of cancer. 
This is a type of cancer with a high rate 
of surgical procedures, with 30.5% of 
cases having a surgical procedure. 
The most frequent are radical nefrec-
tomy and total unilateral nefrectomy.  
Fewer than 10% of these cases have 
intravenous chemotherapy (1-6 hours) 




A total of 13,342 cases (7.4% of all can-
cer cases) were hospitalized for gastric 
cancer, for which the majority were 
treated as inpatient (12,583) and 759 as 
day-hospital care.  
The total number of services received 
was 1,205, with a mean of 5.8 sessions 
per case.  
An important percentage of cases 
(32.9%) are over 70 years old. This can-
cer type affects men more than other 
cancers, as 66, 2% from all discharges 
are men.  
The ALOS is higher than the mean (8.3 
days comparing to 7), and the number 
of emergency admissions is also high 
(30.4%).  
For the 21.8% of cases with surgical 
procedures, more often were performed 
procedures like total gastrectomy and 
exploratory laparatomy. 
About 1/3 of cases had intravenous che-
motherapy (1-6 hours) recorded as sec-
ondary procedure.  
 
 
From all inpatients with CRC, to 
23.2% were performed some surgical 
procedures, and the most frequent 
was the right hemi-colostomy with 
anastomosis and the limited excision 
of large bowel with anastomosis.  
Intravenous chemotherapy (1-6 
hours) was reported as secondary 
procedure for 9,667 cases. 
 
Lung cancer (LC) 
 
For this pathology 34,059 inpatients 
were reported. In addition 2,694 were 
treated as day-hospital, with a mean 
of 10.1 sessions per case. 20.9% from 
inpatient cases are over 70 years old.  
An important finding is that lung can-
cer is more frequent in men than in 
women, 81.5% of discharges are 
men, comparing to 53.5% for all can-
cer cases. For this type of cancer an 
important percentage come from ru-
ral areas (42.8%). 
From all inpatients with LC, to 5.2% 
were performed some surgical proce-
dures, and the most frequent were 
lung lobotomy and fibro-
bronchoscopy with biopsy. Neverthe-
less, a large number of cases (12,413) 
have intravenous chemotherapy (1-6 
hours) reported as secondary proce-
dure, and 11,020 cases have injec-
tions with steroids. 
 
Non-Hodgkin lymphoma (NHL) 
 
There was a total of 16,941 cases 
hospitalized (about 9% from all can-
cer cases), from which 1,721 NHL 
cases were treated in day-hospital 
settings, with a mean of 7 sessions 
per case. 
For this type of cancer more patients 
have to travel for receiving hospital 
care, since 42.9% are residents in 
other districts than the one where 
hospital is located. The ALOS is 5.6 
days, shorter with 1.4 days than the 
average for all cancer types. 
Most of the patients (54.5%) are ad-
mitted with referral from the family 
doctor, and not from the specialist, as 
expected according to situation for 
other types of cancer. 
Only 2% of cases with NHL have 
surgical procedures, like the biopsy 
of lymphatic node and the excision of 
cervical lymphatic nod. 
Over 5,000 cases have reported intra-
venous chemotherapy (1-6 hours) as 
secondary procedure, and over 5,800 
cases injections with steroids. 
 
Chronic Lymphatic Leukemia (CLL) 
 
A total of 14,774 cases (7.3% of all 
cancer cases) were hospitalized in 
2008. A number of 2,357 cases were 
treated as day-hospital, accounting for 
2,900 services, with a mean of 2.7 
sessions per case.  
The majority of cases have no surgi-
cal procedures. Intravenous chemo-
therapy (1-6 hours) was reported for 
2,214 cases. 
 
Pancreas cancer  
 
A number of 6,789 cases were treated 
as inpatient and 605 cases as day-
hospital, with a mean number of 10.5 
sessions per case. More men (60.7% 
of cases) were hospitalized for this 
type of cancer and the ALOS is 
slightly higher than the mean for all 
cancers – 7.2 days comparing to 7 
days.  
The percentage of cases admitted on 
emergency basis is higher than the 
mean for all cancer types, with 36.8% 
versus 21%.  
From all cases with pancreas cancer, 
22.6% have a surgical procedure. 
For 18% of cases intravenous chemo-





Although with lower volume of cases 
than for other types of cancer (6,093 
inpatients and 380 cases treated in 
day-hospital), this type of cancer 
could be very important since the in-
patients are obviously younger than 
for other types of cancer (only 10.9% 
are over 70 years old, comparing to 
25% the mean percentage for all can-
cer types).  
Additionally, more patients need to 
travel in other district for hospitaliza-
tion (48.7%).  
ALOS is longer (8.2 days) than for 
other types of cancer.  
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From a total of 10,178 cases (5.1% 
of all cancer cases), 8,729 cases were 
inpatient and 1,449 cases were 
treated as day-hospital. Patients with 
prostate cancer appear to be older 
than the average for all types of can-
cer, since 56.7% are over 70 years 
old. They are more often admitted as 
emergency than other patients with 
cancer, and they stay less in hospital 
(ALOS of 6 days). The most frequent 
surgical procedures performed on 
these patients were bilateral orhidec-
tomy and transurethral resection of 
prostate. About 39% of patients un-
derwent a surgical procedure. 
 
Cervix and ovarian cancer 
 
In 2008, a number of 19,506 cases 
having a diagnosis of a cervix cancer 
were hospitalized, and 10,944 of 
cases had a malignant ovarian tumor.  
 
D istribution of hospital re-sources for cancer care 
In 2007 a number of 3,420 hospital 
beds were available in oncology 
wards, nationwide. In spite of this 
apparently large number of beds, an 
analysis of geographic distribution 
pointed out that there is a wide ineq-
uity among districts in the available 
number of beds. Although all dis-
tricts have at least one oncology 
ward in hospitals, some districts have 
a very small number of oncology 
beds (for example Giurgiu with 5 
beds), some others, as the university 
centers, have the highest number of 
oncology beds. Bucharest has a num-
ber of 775 beds, highest of all dis-
tricts. There was an average of 81 
beds per district, with a median of 
50. A large variation among districts 
from the point of view of volume of 
oncology beds is shown by the 
41.5% coefficient of variation. The 
university centers, like Bucharest, 
Cluj, Timisoara, Iasi have the highest 
number of beds, with Bucharest hav-
ing 7 oncology wards.  
As a general feature, most hospital 
facilities designated for oncology are 
concentrated nearby university cen-
ters, mostly in the middle of the 
country and in Bucharest. People with 
cancer diseases from remote areas, 
peripheral districts, need to travel of-
ten long distances at regular intervals 
to receive specialized care in hospi-
tals. 
 
C onclusions In Romania, case-mix data can 
be used to show the real burden of 
cancer, in terms of evolution of the 
volume of cases per types of cancers, 
and for various diagnoses, and could 
be used in further studies for the esti-
mation of the economic burden asso-
ciated with the disease. A profile of 
the patient with a certain type of can-
cer can be drawn. Available data 
shows that the most frequent types of 
cancer are breast, colorectal and lung 
cancer. Prostate cancer, currently on 
the third place as volume of cases in 
the European countries, is placed only 
on the eight place in Romania.   
A quarter of cancer patients are over 
70 years old, with higher percentages 
of this age group for colorectal, gas-
tric and prostate cancer. Brain cancer, 
kidney and lung cancer affect more 
the younger population. Colorectal 
cancer, pancreas, breast cancer, brain 
and kidney cancer are very often asso-
ciated with higher volumes of surgical 
procedures performed (over 20% of 
cases). Intravenous chemotherapy is 
most common procedure reported 
among all types of cancer patients. 
Analysis revealed some important 
issues that need to be addressed in 
future. One of them is the inequity in 
access of patients from various re-
gions of the country, especially the 
remote zones, to the specialized on-
cology care in hospitals. For these pa-
tients day-hospital care is not accessi-
ble, and most of them need to be hospi-
talized even for short periods, so that 
services like chemotherapy, administra-
tion of cancer drugs could be accessed 
by these patients. Especially for this 
category, newly available oral drug 
therapies may represent a viable alter-
native to improve access to care.  
Another issue is the high cost of cancer 
treatment, including cost of hospitaliza-
tion, drug therapies, but even more im-
portant, the non-medical and indirect 
costs such as transportation, time of 
caregivers, loss of productivity due to 
disease. Some studies estimated that 2/3 
of cancer costs arise from indirect costs, 
showing this is the main burden on so-
ciety. For this matter, costs of new drug 
therapies, which are often quite high, 
can offset the long term cost of disease 
and societies should be aware of the 
benefits of such therapies in the long 
run. Other barriers in patient access to 
new oncology drugs come from delays 
with the reimbursement process, fol-
lowing introduction of new drug on the 
market. 
The cost of medical care in hospital 
might be high, considering the length of 
stay and procedures delivered. How-
ever, the lack of data on costs of hospi-
tal services at national level makes dif-
ficult an estimation of the economic 
burden of cancer in Romania. A func-
tional National Cancer Registry (still 
under development) and additional re-
sources for treatment in outpatient set-
tings can provide evidence for resource 
allocation and even reduce costs in hos-
pitals, and most important, improve 
accessibility of patients to treatment. 
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